+ Watch NBS
on My Watchlist
Neostem has inexplicably survived a disgustingly large dilutive financing with their share price largely intact, so I can only throw up my hands at the irrationality of the market and jump on the bandwagon ahead of PReSERVE data expected in mid 2014. With other outfits like Cytori, Athersys, and BioLineRx in the stem cell soup for myocardial infarction mix, we can hopefully bury this dubious approach before the end of 2014.
NBS has 4 business units- each of which could easily be a company in its own right. They are at the forefront of a new paradigm in treating certain diseases. The current money-maker is Progenitor Cell Therapy (PCT) which is the manufacturing unit using proprietary technology to manufacture stem cells for other pharma companies. This allows NBS to make money while developing their own stem cell therapies. And perfect their manufacturing techniques. The best known unit is Amorcyte due to phase 2 clinical trial of AMR-001 (autologous marrow stem cells f) for acute myocardial infarction. The Athelos unit is developing the lesser know human regulatory T cell therapy approach (patented technology) to immune-mediated diseases (ie, asthma or type 1 diabetes). This Treg technology has been licensed out to other companies, earning money for the development of this novel therapeutic approach. The VSEL unit is developing pluripotent stem cells (very small embryonic-like stem cells) for regenerative therapies (e.g., wounds or bone regeneration). As this is early research, VSEL is partnering with universities and government organizations to learn about these VSELs. Finally, tthrough the relationships with pharma companies developed by PCT or Athelos, NBS could potentially negotiate a favorable development agreement with a larger company to fund clinical development through phase 3 and approval. This approach has worked for other small biotech companies in recent years. As a forerunner in this new field, NBS could bring one of the first 'stem cell' therapies to market in the next 3 to 5 years.
It will take some more time to start moving up but it will happen.
I think it's a well managed company and should out perform the market.
New cardiac technologies to take off
NeoStem is projected to have their first treatment commercialized in 2017.
Allah peanut butter sandwiches;)~
rock solid on the current market pullback. Watch this fly once it gets the chance
Most of the medical profession, maybe not Wall Street, recognizes we've entered a new age in cancer and cardiac care. Thanks to stem cell and genetics research, we're moving from cutting to perhaps curing, or in the very least, offering patients less invasive procedures that may very well help extend their lives.
Highly undervalued considering the amount of potential it has. I'm not religious but you can't bet against a company backed by the Pope either :)
I'm in NY and I know this company. Expect some future stock dilution or debt issues if it stays independent but I expect it will be acquired at some point.
Stem cell expertise.
This is a high risk / high reward extreme speculation, on my part.This is based on current momentum.
Should've put this at five years, long term stem cell research play
More upside than down. Insider buying.
If you can wait three years and have the stomach to get into the stem cell sector, then this stock is probably going to make you a pretty wealthy investor
The process Neostem uses, and the forward momentum they have will result in this stock being a soon to be winner.
Stem cells, dealing w/aging. potential to be the next botox, and naturally? Let's wait and see.
Company has no real commitment to VSEL technology
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions